73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Microbot Medical Inc
Closed
2.12 -0.47
Overview
Share price change
24h
Min
2.07
Max
2.16
Income | -77K -3.6M |
|---|---|
Employees | 20 |
EBITDA | -79K -3.6M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +299.54% upside |
Next Earnings | 23 Mar 2026 |
|---|
Market Cap | 2.7M 143M |
|---|---|
Previous open | 2.59 |
Previous close | 2.12 |
Technical Score
By Trading Central
Confidence
Neutral Evidence
Microbot Medical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Microbot Medical Inc Forecast
Price Target
By TipRanks
299.54% upside
12 Months Forecast
Average 8.75 USD 299.54%
High 12 USD
Low 5.5 USD
Based on 2 Wall Street analysts offering 12 month price targets forMicrobot Medical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Microbot Medical Inc
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Live chat